Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients of both sexes aged from 40 to 80 years old.~2. COPD diagnosed (in accordance with the GOLD-2014 guidelines) ≥12 months before inclusion.~3. Stable course of COPD (≥ 6 weeks free of disease progression).~4. Mild, moderate or severe degree of bronchial obstruction (FEV1/FVC \< 0.7; post-bronchodilator FEV1 ≥30% of predicted value).~5. CSS score ≥2.~6. Stable dose of standard therapy within the preceding 4 weeks.~7. Use of and adherence to contraceptive methods by fertile-age patients of both sexes during the study.~8. Availability of a signed patient information sheet (Informed Consent form) for participation in the trial.~Exclusion Criteria:~1. Earlier diagnosis of intra- or extrathoracic causes of cough (e.g., asthma, malignant neoplasm of lung, tuberculosis, sarcoidosis, α1-antitrypsin deficiency, bronchiectasis, cystic fibrosis, interstitial pulmonary diseases, perennial allergic rhinitis, gastro-oesophageal reflux disease, use of ACE inhibitors, disease of upper respiratory tract, etc.).~2. Cough associated with eating.~3. An exacerbation of COPD, acute upper and/or lower respiratory infection at inclusion or in the previous 4 weeks.~4. Modifications to standard drug therapy (dose escalation, replacement of medicines prescribed or addition of new medications) in the previous 4 weeks.~5. Very severe degree of bronchial obstruction (post-bronchodilator FEV1 \<30% pred or \< 50% and chronic respiratory failure).~6. Haemoptysis.~7. Stroke in the preceding 3 months or stroke with long-term residual neurological deficit within 6 months before study entry.~8. Acute coronary syndrome, myocardial infarction within 6 months before study enrollment.~9. Unstable or life-threatening arrhythmia in the previous 3 months.~10. Acute or chronic heart failure (NYHA (1964) Class III or IV).~11. Presence or suspicion of oncological disease.~12. Body Mass Index (BMI) ≤18 kg/m2 or ≥40 kg/m2.~13. Chronic kidney disease (categories С3-5 А3).~14. Hepatic failure (Child-Pugh class C)~15. Exacerbation or decompensation of a chronic disease that would affect the patient's ability to participate in the clinical trial.~16. For smokers - intention to quit smoking in the next 4 weeks.~17. Allergy/intolerance to any of the components of medications used in the treatment.~18. Course intake of medicines listed in the section 'Prohibited concomitant treatment' for 4 weeks prior to the enrollment in the trial.~19. Participation in other clinical trials within 3 months prior to the enrollment in this study.~20. Patients who, from investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the investigational drug.~21. Other conditions preventing the patient from normal participation (e.g., planned business or other trips).~22. Drug addiction, alcohol use in the amount over 2 units of alcohol a day, mental diseases.~23. Pregnancy, breast-feeding, unwillingness to use contraception during the study.~24. Patient is related to the research staff of the clinical investigative site who are directly involved in the trial or is the immediate family member of the investigator. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.~25. Patient works for MATERIA MEDICA HOLDING company (i.e., is the company's employee, temporary contract worker or appointed official responsible for carrying out the research or their immediate family).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rengalin (Type: EXPERIMENTAL): Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
- Placebo (Type: PLACEBO_COMPARATOR): Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete